Navigation Links
CV Therapeutics Reports 2008 Third Quarter Financial Results
Date:11/6/2008

- Ranexa(R) net revenue grows 19 percent quarter-over-quarter -

PALO ALTO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today reported financial results for the third quarter ended September 30, 2008.

For the quarter ended September 30, 2008, the Company reported a net loss of $25.4 million, or $0.41 per share. This compares to a net loss of $34.2 million, or $0.58 per share, for the same quarter in 2007 and $4.3 million, or $0.07 per share, for the prior quarter ended June 30, 2008. Excluding the impact of the $22.0 million milestone revenue recognized in the quarter ended June 30, 2008, the prior quarter net loss would have been $26.3 million. The milestone payments received in the second quarter of 2008 were $12.0 million from Astellas Pharma U.S. Inc. (Astellas) associated with the U.S. Food and Drug Administration approval for Lexiscan(R) (regadenoson) injection and $10.0 million relating to a milestone payment from TPG-Axon Capital associated with the commercial launch of Lexiscan(R).

For the quarter ended September 30, 2008, the Company recorded $30.3 million of net product sales of Ranexa(R) (ranolazine extended-release tablets) in the U.S., which represents an increase of 19 percent compared to the $25.4 million of net product sales recorded in the prior quarter ended June 30, 2008 and an increase of 65 percent compared to the $18.4 million of net product sales recorded in the same quarter in the prior year.

For the quarter ended September 30, 2008, the Company recorded total revenues of $38.1 million, which consisted of $30.3 million of net product sales of Ranexa, $4.7 million of royalty and license revenue and $3.2 million of collaboration, milestone and other reve
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
2. According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
3. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
4. Nile Therapeutics to Present at Two Upcoming Investor Conferences
5. Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
6. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
8. United Therapeutics Reports Third Quarter 2008 Financial Results
9. Arete Therapeutics Bolsters Management Team
10. Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics
11. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Selexis SA, a serial innovation company ... (RCBs) used for drug discovery to commercial manufacturing, announced ... Next-Generation Sequencing (NGS) data packages. The NGS ... by ensuring the integrity of the gene, validation of ...
(Date:1/22/2015)... , Nueva Jersey , 22 de enero de ... Biomedical Research abre hoy su llamada a nominaciones para ... investigación científica ha hecho, o tiene el potencial para ... humana. Las nominaciones se aceptarán hasta el 15 de ...
(Date:1/22/2015)... ALTO, Calif. , Jan. 22. 2015  Varian Medical Systems ... and software, has been honored for its commitment to sustainability ... sustainable companies. Varian is the highest ranked healthcare equipment company ... announced today during the World Economic Forum at ...
(Date:1/22/2015)... , Jan. 22, 2015  Derma Sciences, Inc. (Nasdaq: ... focused on advanced wound care, announces that AMNIOEXCEL® ... have been added to the Premier, Inc. Regenerative ... opportunity for the AMNIOEXCEL® and AMNIOMATRIX® product lines, ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... In conjunction with,its third quarter 2007 earnings release (expected to ... CVD ) is pleased to invite you to,listen to ... the Internet on Thursday, October 25 at 9:00 a.m. ET. ... and Slide Presentation When: October 25, 2007, ...
... Pharmasset, Inc.,(Nasdaq: VRUS ) has entered into ... Subject to certain terms and conditions of,the agreement, Horizon ... At its option, Pharmasset may receive a second loan ... loan of $10 million by November 30, 2008,provided conditions ...
... Inc.,(Nasdaq: COHR ) today announced that, as anticipated, ... Determination letter indicating that,the Company is not currently in ... Rules 4350(e) and 4350(g) due to,its failure to hold ... September 30, 2007. The notice stated that the failure ...
Cached Biology Technology:Pharmasset Accesses up to $30 Million of Working Capital 2Pharmasset Accesses up to $30 Million of Working Capital 3Coherent, Inc. Receives Expected Letter from NASDAQ 2
(Date:12/17/2014)... is fundamentally transforming the travel experience and nowhere is ... past decade, ePassports, biometric readers, and secure document scanners ... control via eGates and Automated Passport Control (APC) Kiosks ... borders across the globe. According to ...
(Date:12/11/2014)... and Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... the addition of the "Biometrics Market in the ... One major trend emerging in this market is ... is important to upgrade biometric solutions to the latest ...
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays a role ... Hypertension – the medical term for high blood pressure – ... and the inflatable cuff that,s used in measuring blood pressure ... there,s nothing new about hypertension, its triggers and its effects. ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... tote their latest fossil discovery from the field to ... stored on a laptop. But sharing that data as ... are currently lacking, say paleontologists at Southern Methodist University ... scanning technology to capture field data of a huge ...
... least 60% of waste paper and cardboard collected must be ... 22.5% of plastics. However, a study by researchers at the ... requirement is only exceeded in the case of glass. ... 45% in the best of cases, at a maximum distance ...
... scientists has discovered that human-introduced, invasive species of plants ... professor of biology at Penn State University, and Jason ... have studied how invasive fruiting plants affect ecosystems and ... be beneficial to an ecological community. The team,s research, ...
Cached Biology News:3-D digital dinosaur track download: A roadmap for saving at-risk natural history resources 23-D digital dinosaur track download: A roadmap for saving at-risk natural history resources 33-D digital dinosaur track download: A roadmap for saving at-risk natural history resources 4Spanish cities fail to meet legal requirements on paper and container recycling 2Invasive plants can create positive ecological change 2Invasive plants can create positive ecological change 3Invasive plants can create positive ecological change 4
... Arginine methylation is an irreversible post ... linked to protein activity. At least three ... in mammalian cells. These enzymes have been ... methylation of key proteins in several fundamental ...
... Biotinylation Kit, Plasmid is designed for use with ... kits. (Cat. No. 3 186 148, 3 186 ... for the easy introduction of a C- or ... be enzymatically mono-biotinylated by E. coli biotin protein ...
... the major proteolytic system in the ... catalyzes the selective degradation of short-lived ... of proteins with abnormal conformation (Hershko ... critical protease in this pathway is ...
... sensitive, fast and specific detection of chromosomal ... Short hybridisation time ( ... Multiplex capability Available with different ... Probes available with different labels. Related ...
Biology Products: